A Phase 1 interventional study of Calderasib and Midazolam in Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc — 14 open to participants now, 26 under way, 18 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck & Co., Inc.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 79th largest by enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2024, is one of 19 in phase 1, and was the 81st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →14 of the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Brazil and 17 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Argentina, Australia, Brazil and 16 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 8 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 27 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 30 · Phase 3 40 · Phase 4 1
First in 2000; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 149 across the 88 interventional studies, 600 across the 3 observational. Of the 65 that completed or were terminated, 49 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
3 of the studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05609968Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | 2027-01-12 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT06074588Phase 3Merck Sharp & Dohme LLCSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | 2027-05-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to midazolam and digoxin in the body when it is given with and without another medicine called calderasib. Researchers are testing if digoxin and midazolam levels in the body are different when digoxin and midazolam are given with or without calderasib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of midazolam and a single oral dose of digoxin on Day 1.
Drug: Midazolam · Drug: Digoxin
A washout period of at least 10 days will occur following midazolam and digoxin dosing in Period 1 and the first calderasib dosing in Period 2. Participants will receive calderasib once daily on Days 1 through Day 15 with a single oral dose of midazolam on Days 1, 6, and 14 and a single oral dose of digoxin on Days 1 and 11.
Drug: Calderasib · Drug: Midazolam · Drug: Digoxin
Oral administration
Also known as: MK-1084
Oral administration
Oral administration
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Midazolam
Blood samples will be collected to determine the AUC0-inf of midazolam.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Midazolam
Blood samples will be collected to determine the AUC0-last of midazolam.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hr) of Midazolam
Blood samples will be collected to determine the AUC0-24hr of midazolam.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Maximum Plasma Concentration (Cmax) of Midazolam
Blood samples will be collected to determine the Cmax of midazolam.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Time to Maximum Plasma Concentration (Tmax) of Midazolam
Blood samples will be collected to determine the Tmax of midazolam.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Apparent Terminal Half-life (t1/2) of Midazolam
Blood samples will be collected to determine the t1/2 of midazolam.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Apparent Clearance (CL/F) of Midazolam
Blood samples will be collected to determine the CL/F of midazolam.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Midazolam
Blood samples will be collected to determine the Vz/F of midazolam.
Time frame: Predose and at designated timepoints up to 24 hours postdose
AUC0-Inf of Digoxin
Blood samples will be collected to determine the AUC0-inf of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
AUC0-Last of Digoxin
Blood samples will be collected to determine the AUC0-last of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
AUC0-24hr of Digoxin
Blood samples will be collected to determine the AUC0-24hr of digoxin.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Cmax of Digoxin
Blood samples will be collected to determine the Cmax of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Tmax of Digoxin
Blood samples will be collected to determine the Tmax of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
t1/2 of Digoxin
Blood samples will be collected to determine the t1/2 of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
CL/F of Digoxin
Blood samples will be collected to determine the CL/F of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Vz/F of Digoxin
Blood samples will be collected to determine the Vz/F of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
AUC0-24hr of Calderasib
Blood samples will be collected to determine the AUC0-24hr of calderasib.
Time frame: Predose and at designated timepoints up to 24 hours postdose
AUC0-Last of Calderasib
Blood samples will be collected to determine the AUC0-last of calderasib.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Cmax of Calderasib
Blood samples will be collected to determine the Cmax of calderasib.
Time frame: Predose and at designated timepoints up to 24 hours postdose
C24 of Calderasib
Blood samples will be collected to determine the Cmax of calderasib.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Tmax of Calderasib
Blood samples will be collected to determine the Tmax of calderasib.
Time frame: Predose and at designated timepoints up to 24 hours postdose
t1/2 of Calderasib
Blood samples will be collected to determine the t1/2 of calderasib.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Cmax Accumulation Ratio of Calderasib
Blood samples will be collected to determine the Cmax accumulation ratio of calderasib. The accumulation ratio is the ratio of Predose Cmax to the 24 hour Cmax
Time frame: Predose and at designated timepoints up to 24 hours postdose
AUC0-24 Accumulation Ratio of Calderasib
Blood samples will be collected to determine the AUC0-24 accumulation ratio of calderasib. The accumulation ratio is the ratio of Predose AUC0-24 to the 24 hour AUC0-24.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Amount of Drug Excreted in Urine from Time 1 to Time 2 (Aet1-t2) of Digoxin
Urine samples will be collected to determine the Aet1-t2 of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Total Amount of Drug Excreted in Urine (Ae) of Digoxin
Urine samples will be collected to determine the Ae of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Fraction of Unchanged Digoxin in Urine (Fe)
Urine samples will be collected to determine the Fe of digoxin.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 1 month
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.
Time frame: Up to approximately 1 month
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2024 to primary completion in Oct 2024, 1 month.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 1 month is below that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Midazolam · Digoxin
Carcinoma, Non-Small-Cell Lung →